Current Chemotherapeutic Management of Patients with Gestational Trophoblastic Neoplasia

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="2"><hr/></td></tr><tr><td align="left"><i>Low risk </i></td><td align="left"></td></tr><tr><td align="left"> Initial therapy</td><td align="left">Sequential MTX/ACT-D</td></tr><tr><td align="left" rowspan="2"> Resistant therapy</td><td align="left">MAC or EMA/CO</td></tr><tr><td align="left">Surgery, as indicated</td></tr><tr><td align="center" colspan="2"><hr/></td></tr><tr><td align="left"><i>High risk </i></td><td align="left"></td></tr><tr><td align="left"> Initial therapy</td><td align="left">EMACO</td></tr><tr><td align="left" rowspan="3"> Resistant therapy</td><td align="left">EMAEP</td></tr><tr><td align="left">VBP</td></tr><tr><td align="left">Surgery, as indicated</td></tr><tr><td align="center" colspan="2"><hr/></td></tr><tr><td align="left" rowspan="2">Followup</td><td align="left">12 consecutive months of undetectable hCG levels</td></tr><tr><td align="left">Contraception for 12 months</td></tr><tr class="table-tr"><td colspan="2"><hr class="tbody-hr"/></td></tr></table></td></tr><tr class="table-fn"><td>ACT-D: actinomycin D; EMACO: etoposide, methotrexate, actinomycin D, cytoxan, oncovin; EMAEP: etoposide, methotrexate, actinomycin D, carboplatin; MAC: methotrexate, actinomycin D, cytoxan; MTX: methotrexate; VBP: vinblastine, bleomyCin, carboplatin.<br/></td></tr></table>

Treatment protocol for stages II and III gestational trophoblastic neoplasia (New England Trophoblastic Disease center).

Chemotherapy Research and Practice

tab4

Table 4

Table 4: Current Chemotherapeutic Management of Patients with Gestational Trophoblastic Neoplasia 